Author MStranslate

MStranslate co-founder, Brett Drummond, explores and explains a recently published research paper that has identified COVID-19 infection as a potential trigger for multiple sclerosis. While the outcomes of...

Late in 2022, we published two new videos that provided insights on the topic of remyelination research in multiple sclerosis (MS). The first video was recorded at the European Committee for Treatment and...

At the recent European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress, Belinda Bardsley (Austin Health, Australia) presented on a research study that assessed the impact...

The 38th meeting of the European Congress for the Treatment and Research Into Multiple Sclerosis (ECTRIMS) took place in Amsterdam, The Netherlands, between the 26th and 28th of October, 2022. The ECTRIMS...

On September 25, 2022, our co-founder and chief science communicator, Brett Drummond, took to Facebook Live with a very special guest, Dr Travis Stiles (CEO, Novoron Bioscience). Many who follow MStranslate...

Research Summary: Repurposing the cardiac glycoside digoxin to stimulate myelin regeneration in chemically-induced and immune-mediated mouse models of multiple sclerosis The ability to repair myelin damage...

In this third instalment of our video series on Epstein-Barr virus (EBV) and its potential role in multiple sclerosis (MS), our co-founder and chief science communicator, Brett Drummond, explores a Stanford...

Research Update: ATA188 Phase 2 EMBOLD Study Today, Atara Biotherapeutics provided an update on their Phase 2 randomised clinical trial, called the EMBOLD study, which is testing the safety and effectiveness...

Research Summary: Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM New studies linking Epstein-Barr virus (EBV) to multiple sclerosis have been the biggest research news of...

We often hear the term 'biomarker' used in medical research, but what does it mean? In the video below, our co-founder and chief science communicator, Brett Drummond, answers this very question. As part of...